Goldman Sachs & Co. LLC has recently announced that it has increased stake in ZyVersa Therapeutics Inc. (NASDAQ:ZVSA) by 61.02%. After grabbing 0.1 million shares, the institutional investor is now in possession of 39213.0 shares of the Healthcare Company. The new investment brought the stake of investor firm to 0.51% having worth around $48114.0. Moreover, EdgeHill Partners increased its share by 17126.0 to have a control over 17126.0 shares. And The Vanguard Group, Inc. raised its holdings to 16894.0 shares by acquiring 16894.0 shares or 0.08% of the stake.
ZyVersa Therapeutics Inc. (ZVSA) concluded trading on 05/24/23 at a closing price of $0.44, with 1.24 million shares of worth about $0.54 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -95.72% during that period and on Wednesday the price saw a gain of about 1.30%. Currently the company’s common shares owned by public are about 9.13M shares, out of which, 4.15M shares are available for trading.
Unlock the Hottest Top 10 Penny Stocks Today! Discover Now
Dive into the world of lucrative penny stocks with MarketClub's groundbreaking "Smart Scan" technology! Get an instant snapshot of the top 50 high volume stocks with a clear direction and outstanding liquidity - in other words, the strongest trending. To unlock this exclusive list, simply provide your first name, last name, and email for instant access.
Gain Access to Top 10 Penny Stocks Now!.
Sponsored
According to filings with the U.S. Securities and Exchange Commission (SEC), insiders took part in trade of the company’s stock for 9 times over the past 12 months. They bought 3,565,310 shares in 9 of the transactions. In 0 selling transactions, insiders dumped 0 shares.
RiverNorth Opportunities Fund Inc, EHP Global Arbitrage Alternative, and Vanguard Extended Market Index Fu are the top 3 mutual funds which are holding stakes in ZyVersa Therapeutics Inc. RiverNorth Opportunities Fund Inc is currently holding 48471.0 shares of worth totaling $22539.0. The company recently came selling 16157.0 shares which brought its stake up to 0.24% of the company’s outstanding shares. Vanguard Extended Market Index Fu, after buying 17194.0 shares, have now control over 0.09% of the stake in the company. It holds 300.0 shares of worth $7995.0.
However, the stock later moved at a day high price of 0.4600, or with a gain of 1.30%. Stock saw a price change of 16.16% in past 5 days and over the past one month there was a price change of -72.94%. Over the period of past 52 weeks, stock dropped to lowest price of $0.37 but also hit the highest price of $25.00 during that period. The average intraday trading volume for ZyVersa Therapeutics Inc. shares is 1.48 million. The stock is currently trading -10.05% below its 20-day simple moving average (SMA20), while that difference is down -66.26% for SMA50 and it goes to -92.15% lower than SMA200.
Goldman Sachs & Co. LLC acquired 0.1 million shares of ZyVersa Therapeutics Inc. having value of about $48114.0. Data submitted at the U.S SEC by Goldman Sachs & Co. LLC revealed that the firm now holds 39213.0 shares in the company valued at close to $17253.72, or have control over 61.02% stake in the company. ZyVersa Therapeutics Inc. (NASDAQ: ZVSA) currently have 9.13M outstanding shares and institutions hold larger chunk of about 81.20% of that. Holding of mutual funds in the company is about 0.43% while other institutional holders and individual stake holders have control over 7.24% and 0.36% of the stake respectively.
The stock has a current market capitalization of $7.74M. It has posted earnings per share of -$2.62 in the same period. It has Quick Ratio of 0.30 while making debt-to-equity ratio of 0.00. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for ZVSA, volatility over the week remained 12.78% while standing at 15.56% over the month.
Stock’s fiscal year EPS is expected to drop by -198.60%.
Analysts at 0 brokerage firms have issued recommendations for the ZyVersa Therapeutics Inc. (ZVSA)’s stock out of those 0 Wall Street analysts, 0 recommended a “Buy” rating, while 0 were in favor recommending the stock as a “Hold” and 0 analyst recommended the stock as “Sell”.
